In this webinar, Trish Simner, Associate Professor of Pathology at Johns Hopkins University, will discuss her lab's work on using zebrafish as a model system for studying human disease. The grant her lab will receive will support her research for a year, allowing her to further investigate the potential of zebrafish as a model organism.

The grant will support her research for a year, allowing her to further investigate the potential of zebrafish as a model organism.

Vaccines and therapeutics are crucial in the fight against infectious diseases. In this webinar, Mattia Borsani, a researcher at the European Molecular Biology Laboratory (EMBL), will discuss the development of a new vaccine candidate called VLA15.

Based on these new results, Valneva and Pfizer plan to submit a biologics license application (BLA) to the US Food and Drug Administration (FDA) in the second quarter of 2022. If approved, VLA15 could be the first vaccine against Lyme disease.

Valneva's inactivated, recombinant vaccine strain VLA2001 received a recommendation for approval in December 2021. The European Commission is expected to issue a decision on this recommendation in the second quarter of 2022.

The NHRA and reflects the NHRA's initiative to support innovation in vaccine research and development.

At the end of this presentation, you will have a better understanding of the latest developments in vaccine research and the potential impact of new vaccine candidates like VLA15 on public health.

Meet the researchers:

- Trish Simner, Associate Professor of Pathology at Johns Hopkins University
- Mattia Borsani, Researcher at EMBL

Don't miss this opportunity to learn from experts in the field and gain insights into the future of vaccine research.

Sign up now to secure your spot in this exciting webinar.